Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Tirzepatide cycle length: what human studies ran

FDA-approvedAHuman trial evidence
Short answer: Tirzepatide has no "cycle". As an approved drug it is used as its label and a prescriber direct.

Treatment and follow-up in human studies

  1. SURPASS-1, -2 and -5 were 40-week trials, SURPASS-3 was 52 weeks and SURPASS-4 was 104 weeks (52-week primary endpoint), each with tirzepatide 5, 10 or 15 mg once weekly; SURPASS-PEDS was a 30-week placebo-controlled trial (5 or 10 mg) with a 22-week open-label extension 1.
  2. SURPASS-CVOT followed participants for a median of 210.1 weeks 1.
  3. Zepbound weight-reduction trials: Studies 1 and 2 lasted 72 weeks with an escalation period of up to 20 weeks; Study 3 lasted 84 weeks (12-week intensive lifestyle lead-in, then 72 weeks randomized); Study 4 lasted 88 weeks (36-week open-label lead-in, then 52 weeks randomized withdrawal). The two OSA trials (Studies 5 and 6) lasted 52 weeks, with escalation over up to 20 weeks to 10 mg or 15 mg 2.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Tirzepatide combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Tirzepatide cycle length?
No cycle is defined. Tirzepatide is an approved drug whose label describes treatment under a prescriber's care; the label, not a cycle, governs duration.
What is the longest human study of Tirzepatide?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Tirzepatide dosing reference Full research page

References

  1. MOUNJARO (tirzepatide) injection: prescribing information (Eli Lilly), DailyMed set ID d2d7da5d-ad07-4228-955f-cf7e355c8cc0 FDA label (DailyMed). 2026
  2. ZEPBOUND (tirzepatide) injection: prescribing information (Eli Lilly), DailyMed set ID 487cd7e7-434c-4925-99fa-aa80b1cc776b FDA label (DailyMed). 2026
  3. Drugs@FDA application records for NDA 215866 (Mounjaro) and NDA 217806 (Zepbound): original approval dates Drugs@FDA (via openFDA). 2026
  4. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) N Engl J Med. 2022
  5. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) N Engl J Med. 2021
  6. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) N Engl J Med. 2024
  7. WADA publishes 2027 Prohibited List (news release, 21 September 2026) WADA. 2026
  8. International Standard Prohibited List 2026 WADA Prohibited List. 2026